HYPAQUE ORAL POWDER DIN 02180685
Health Canada record
| Active ingredient(s) | DIATRIZOATE SODIUM 997.4 MG |
|---|---|
| Dosage form | Powder |
| Route | Rectal; Oral |
| Schedule | ETHICAL |
| Class | Human |
| ATC | V08AA01 DIATRIZOIC ACID |
| Original market date | 19-Feb-1998 |
| Current status date | 27-Jul-2011 |
| Source | Health Canada DPD |
Establishment licence of the holder
GE Healthcare Canada Inc. — licence 101469, currently licensed, last inspection rating C (2023-02-06).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DIATRIZOATE SODIUM
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02180626 | HYPAQUE ORAL LIQUID - 50G/120ML | NYCOMED IMAGING A.S. | Liquid | DIATRIZOATE SODIUM 50 G | Cancelled Post Market |
| 02026902 | HYPAQUE ORAL LIQUID 50GM/120ML | SANOFI CANADA, INC. | Liquid | DIATRIZOATE SODIUM 50 G | Cancelled Post Market |
| 02026988 | HYPAQUE ORAL POWDER 0.9974G/G | SANOFI CANADA, INC. | Powder | DIATRIZOATE SODIUM 997.4 MG | Cancelled Post Market |
| 01905007 | HYPAQUE PWR 100% | STERLING WINTHROP INC. | Powder | DIATRIZOATE SODIUM 100 % | Cancelled Post Market |
| 02180650 | HYPAQUE SODIUM 50% - LIQ IV | NYCOMED IMAGING A.S. | Liquid | DIATRIZOATE SODIUM 50 % | Cancelled Post Market |
| 01902768 | HYPAQUE SODIUM 50% LIQ | STERLING WINTHROP INC. | Liquid | DIATRIZOATE SODIUM 50 % | Cancelled Post Market |
| 02017784 | HYPAQUE SODIUM LIQ 50% | SANOFI CANADA, INC. | Liquid | DIATRIZOATE SODIUM 50 % | Cancelled Post Market |
| 02180677 | HYPAQUE-M 76% | AMERSHAM HEALTH INC | Solution | DIATRIZOATE SODIUM 10 %; DIATRIZOATE MEGLUMINE 66 % | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 7857 | 2006-03-29 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 441 | 2002-06-06 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
International API supply for DIATRIZOATE SODIUM
3 active FDA Drug Master Files.
Request a quote for HYPAQUE ORAL POWDER